کد مقاله | کد نشریه | سال انتشار | مقاله انگلیسی | نسخه تمام متن |
---|---|---|---|---|
2570197 | 1128573 | 2010 | 8 صفحه PDF | دانلود رایگان |
عنوان انگلیسی مقاله ISI
Hepatically-metabolized and -excreted artificial oxygen carrier, hemoglobin vesicles, can be safely used under conditions of hepatic impairment
دانلود مقاله + سفارش ترجمه
دانلود مقاله ISI انگلیسی
رایگان برای ایرانیان
کلمات کلیدی
ALTrHSAγ-GTPCCl4RBCHCTTBARSWBCCREPAOH&E - H & Eγ-glutamyltransferase - γ-گلوتامیل ترانسفرازAST - آسپارتات ترانس آمینازAspartate aminotransferase - آسپارتات ترانس آمیناز یا AST Alanine aminotransferase - آلانین آمینوترانسفرازRecombinant human serum albumin - آلبومین سرم خون انسانALP - آلکالن فسفاتازAlkaline phosphatase - آلکالین فسفاتاز یا فسفاتاز قلیاییtriglyceride - تریگلیسریدArtificial oxygen carrier - حامل اسیدهای مصنوعیBUN - خوبmononuclear phagocyte system - سیستم فاگوسیتی تک هسته ایthiobarbituric acid reactive substances - مواد واکنش پذیر اسید تیوباربیتوریکMPs - نمایندگان مجلسurea nitrogen - نیتروژن اورهhematocrit - هماتوکریتhematoxylin/eosin - هماتوکسیلین / ائوزینHemoglobin - هموگلوبینHBV - هپاتیت بpolyethylene glycol - پلی اتیلن گلیکولPEG - پلیاتیلن گلیکول creatinine - کراتینینCarbon tetrachloride - کربن تتراکلریدtotal bilirubin - کل بیلی روبینwhite blood cell - گلبول سفید خونred blood cell - گلبول قرمز، اریتروسیت
موضوعات مرتبط
علوم زیستی و بیوفناوری
علوم محیط زیست
بهداشت، سم شناسی و جهش زایی
پیش نمایش صفحه اول مقاله
![عکس صفحه اول مقاله: Hepatically-metabolized and -excreted artificial oxygen carrier, hemoglobin vesicles, can be safely used under conditions of hepatic impairment Hepatically-metabolized and -excreted artificial oxygen carrier, hemoglobin vesicles, can be safely used under conditions of hepatic impairment](/preview/png/2570197.png)
چکیده انگلیسی
The hemoglobin vesicle (HbV) is an artificial oxygen carrier in which a concentrated Hb solution is encapsulated in lipid vesicles. Our previous studies demonstrated that HbV is metabolized by the mononuclear phagocyte system, and the lipid components are excreted from the liver. It is well-known that many hepatically-metabolized and -excreted drugs show altered pharmaceutics under conditions of liver impairment, which results in adverse effects. The aim of this study was to determine whether the administration of HbV causes toxicity in rats with carbon tetrachloride induced liver cirrhosis. Changes in plasma biochemical parameters, histological staining and the pharmacokinetic distribution of HbV were evaluated after an HbV injection of the above model rats at a putative clinical dose (1400Â mgHb/kg). Plasma biochemical parameters were not significantly affected, except for a transient elevation of lipase, lipid components and bilirubin, which recovered within 14Â days after an HbV infusion. Negligible morphological changes were observed in the kidney, liver, spleen, lung and heart. Hemosiderin, a marker of iron accumulation in organs, was observed in the liver and spleen up to 14Â days after HbV treatment, but no evidence of oxidative stress in the plasma and liver were observed. HbV is mainly distributed in the liver and spleen, and the lipid components are excreted into feces within 7Â days. In conclusion, even under conditions of hepatic cirrhosis, HbV and its components exhibit the favorable metabolic and excretion profile at the putative clinical dose. These findings provide further support for the safety and effectiveness of HbV in clinical settings.
ناشر
Database: Elsevier - ScienceDirect (ساینس دایرکت)
Journal: Toxicology and Applied Pharmacology - Volume 248, Issue 3, 1 November 2010, Pages 234-241
Journal: Toxicology and Applied Pharmacology - Volume 248, Issue 3, 1 November 2010, Pages 234-241
نویسندگان
Kazuaki Taguchi, Mayumi Miyasato, Hayato Ujihira, Hiroshi Watanabe, Daisuke Kadowaki, Hiromi Sakai, Eishun Tsuchida, Hirohisa Horinouchi, Koichi Kobayashi, Toru Maruyama, Masaki Otagiri,